EXPRESSION OF MRNA CD16A, CD16B, ICAM1, CD38, FOXP3 IN TUMOR TISSUE OF PATIENTS WITH CLEAR CELL RENAL CELL CARCINOMA

Introduction. Diagnosis of kidney cancer presents significant difficulties, since symptoms of the disease may appear only at an advanced stage. Increasing attention is paid to the search for markers that allow for rapid and effective tumor diagnosis and disease prognosis, including the determination of expression of messenger ribonucleic acid (mRNA) of genes regulating the immune response. The aim of the study was to evaluate the expression of CD16A, CD16B, ICAM1, CD38, FOXP3 mRNA in tumors of patients with clear cell renal cell carcinoma. Material and methods. The study included 400 patients aged 45-68 years with histologically confirmed clear cell renal cell carcinoma, mainly stage I-II (73%, 292/400), G2 – 57.3% of observations (229/400). Most patients underwent radical nephrectomy (279/400 – 69.8%). All patients signed an informed consent before the study. Tumor tissue samples (3 mm³) were collected on the day of surgery. The mRNA level was determined in the obtained samples in real time using reverse transcription-polymerase chain reaction and calculated in relative units. The ubiquitin ligase C (UBC) gene was used as a housekeeping gene and as a positive control. Statistical processing of the results was performed using Statistica v.10.0 and MS Excel 2010. Results. The most frequently detected mRNA expression in the tumor tissue was CD16A (100%), CD38 mRNA (93.3%, 280/300), CD16B mRNA (92%, 276/300), and the least frequently detected mRNA was FOXP3 (56%, 168/300). The detection frequency of ICAM1 mRNA was 84.7% (254/300). When assessing the detection of gene mRNA in patients with different sizes of the primary lesion according to the TNM system, different stages of the disease, prognosis, degree of tumor malignancy and different outcomes of the disease, the detected differences in detection persisted. The frequency of FoxP3 mRNA  detection increased in patients with stage IV tumors, but remained lower than the frequency of CD16A, CD16B, ICAM1, CD38 mRNA detection. Conclusions. In tumors of patients with clear cell renal cell carcinoma, a high frequency of CD16A, CD16B, CD38 mRNA detection and low expression of FoxP3 mRNA were detected regardless of a number of clinical and morphological predictors of disease prognosis.

1. https://pubmed.ncbi.nlm.nih.gov/33994165/

2. [https://doi.org/10.1016/j.euf.2021.04.014]https://pmc.ncbi.nlm.nih.gov/articles/PMC11782763/

3. [https://doi.org/10.1007/s12672-025-01831-w]https://www.nature.com/articles/nprot.2006.83 [https://doi.org/10.1038/nprot.2006.83]

4. https://pubmed.ncbi.nlm.nih.gov/30655272/ [https://doi.org/10.1182/blood-2018-07-864538]

5. https://pmc.ncbi.nlm.nih.gov/articles/PMC6764113/

6. [https://doi.org/10.3389/fimmu.2019.02155]https://pubmed.ncbi.nlm.nih.gov/28247912/ [https://doi.org/10.1002/ijc.30671]

7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9728583/ [https://doi.org/10.3389/fonc.2022.1052672]

8. https://pubmed.ncbi.nlm.nih.gov/29313949/ [https://doi.org/10.3322/caac.21442]

9. https://pmc.ncbi.nlm.nih.gov/articles/PMC6792391/ [https://doi.org/10.1002/JLB.2MR1218-501R]

10. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1238312/full [https://doi.org/10.3389/fimmu.2023.1238312]